Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR
- DOI
- 10.1038/s41591-025-04117-4
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/1b4e137a-3806-482e-bec0-96c6c4d6c24d is authoritative.
How this rating was calculated
- IntegrityIntegrity concern−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- No reported statistical tests were found to recompute.
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 14 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy endpoint is the percentage change from baseline in CSF mutant huntingtin (mHTT) levels, a surrogate biomarker. The paper does not provide validated evidence linking CSF mHTT reduction to clinical outcomes in HD, and although target engagement is shown (pseudoexon inclusion, PK/PD modeling), the link to clinical benefit is not established. The study was terminated early and no clinical efficacy was demonstrated.
“The primary outcome, a decrease in cerebrospinal fluid mutant HTT levels versus placebo, was summarized descriptively, making branaplam the first splicing modulator to lower mutant HTT levels in the cerebrospinal fluid of individuals with HD.”
- 02Treatment effect not shown to be clinically meaningful
The reported effect is a 25.2% placebo-corrected reduction in CSF mHTT at week 17. The paper states that a 30-50% reduction is expected to slow disease progression, and modeling indicated that no lower dose would achieve at least 30% lowering. Thus, the observed effect is below the threshold for expected clinical benefit, and no clinical meaningfulness is established.
“At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81), indicating a 25.2% placebo-corrected lowering of mHTT levels in the CSF.”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper is a well-conducted phase 2b randomized, double-blind, placebo-controlled trial with rigorous design, clear ethical approvals, and transparent reporting. The main weaknesses are minor reporting gaps: lack of explicit reporting guideline statement, missing confidence intervals for the primary endpoint, and unspecified NHP housing conditions.
Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence was present. The statistics verification component found no recomputable tests (total=0), so statistical correctness was not independently verified; the citation component found no retracted or unresolved references.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
- lowinternal contradictionThe abstract states '18 (85.7%) showed at least one sign or symptom of peripheral neuropathy' while the results section states '18 of 21 (85.7%) participants who received branaplam 56 mg weekly had at least one sign or symptom potentially indicative of peripheral neuropathy'. These are consistent, but the abstract omits the denominator.
“18 (85.7%) showed at least one sign or symptom of peripheral neuropathy.”
AbstractFind in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewer 1The observed lateral ventricle volume increase is likely due to lowering wild-type HTT, not neurotoxicity.The paper presents arguments (reversibility, lack of brain tissue loss) but acknowledges uncertainty, so the claim is partially supported.Evidence: Discussion presents arguments for HTT lowering effect but states 'It is not known whether the observed volume increase is due to changes in CSF flow dynamics... or whether this is due to a neurotoxic effect'.
“It is not known whether the observed volume increase is due to changes in CSF flow dynamics as a consequence of lowering wild-type HTT levels or whether this is due to a neurotoxic effect related to branaplam.”
DiscussionFind in source - partialReviewer 2The increase in lateral ventricle volume is likely due to lowering wild-type HTT, not neurotoxicity.The paper offers indirect evidence (reversibility, lack of brain tissue loss) but acknowledges uncertainty.Evidence: Discussion section argues for a non-neurotoxic mechanism based on reversibility and lack of associated symptoms.
“The rapid onset and reversibility of the effect, the lack of detectable loss of brain tissue, as indicated by other volumetric MRI measures, and the absence of any associated symptoms (for example, cognitive decline, confusion, gait problems) argue in favor of this being a consequence of lowering the wild-type HTT levels”
Discussion ¶4Find in source - supportedReviewers 1, 2Branaplam lowers mutant huntingtin levels in CSF of people with HD.The paper reports a placebo-corrected lowering of 25.2% at week 17, which is consistent with the claim.Evidence: Results section reports mean percentage change from baseline in CSF mHTT: -22.3% (branaplam) vs -6.4% (placebo) at week 9, and -26.6% vs -1.4% at week 17, with a difference of -25.2%.
“At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81), indicating a 25.2% placebo-corrected lowering of mHTT levels in the CSF.”
ResultsFind in source - supportedReviewers 1, 2Branaplam treatment is associated with signs of peripheral neuropathy.The paper reports that 85.7% of branaplam-treated participants had signs or symptoms of peripheral neuropathy, which is a clear association.Evidence: Results section reports 18 of 21 (85.7%) participants had at least one sign or symptom potentially indicative of peripheral neuropathy.
“18 of 21 (85.7%) participants who received branaplam 56 mg weekly had at least one sign or symptom potentially indicative of peripheral neuropathy”
ResultsFind in source - supportedReviewers 1, 2The safety signal led to early termination of the trial.The paper clearly states that the safety signal and modeling results triggered early termination.Evidence: Abstract and Results state that the safety signal and dose-modeling results triggered early termination.
“This safety signal, along with dose-modeling results triggered the early termination of VIBRANT-HD.”
AbstractFind in source - supportedReviewer 1NfL is a useful early biomarker for peripheral neurotoxicity.The paper shows that NfL elevations preceded or accompanied neuropathy signs in NHPs and humans, supporting its utility.Evidence: NHP studies show increased NfL before histological changes; clinical data show NfL elevations in most branaplam-treated participants.
“Our preclinical data in NHPs, which showed an increase in NfL levels before any histological change, supported such use of NfL as an early exploratory clinical trial safety biomarker.”
DiscussionFind in source - supportedReviewer 2The translational PK-PD model predicted that no lower dose would achieve sufficient mHTT lowering.The paper presents modeling results showing that no regimen would lead to at least 30% lowering of CSF mHTT.Evidence: Results section describes the modeling and simulation work showing none of the regimens would lead to at least 30% lowering.
“The modeling and simulation work showed that, while some regimens could lead to less branaplam exposure than 56 mg once weekly, potentially with a better safety profile (Fig. ), none of those regimens would lead to at least 30% lowering of CSF mHTT (Fig. ).”
ResultsFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy endpoint is the percentage change from baseline in CSF mutant huntingtin (mHTT) levels, a surrogate biomarker. The paper does not provide validated evidence linking CSF mHTT reduction to clinical outcomes in HD, and although target engagement is shown (pseudoexon inclusion, PK/PD modeling), the link to clinical benefit is not established. The study was terminated early and no clinical efficacy was demonstrated.
“The primary outcome, a decrease in cerebrospinal fluid mutant HTT levels versus placebo, was summarized descriptively, making branaplam the first splicing modulator to lower mutant HTT levels in the cerebrospinal fluid of individuals with HD.”
- INADEQUATEEffect sizeThe reported effect is a 25.2% placebo-corrected reduction in CSF mHTT at week 17. The paper states that a 30-50% reduction is expected to slow disease progression, and modeling indicated that no lower dose would achieve at least 30% lowering. Thus, the observed effect is below the threshold for expected clinical benefit, and no clinical meaningfulness is established.
“At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81), indicating a 25.2% placebo-corrected lowering of mHTT levels in the CSF.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction extensively cites prior research on HD, HTT lowering strategies, and branaplam's mechanism and preclinical effects. It acknowledges both the promise and the risks (e.g., neurotoxicity in dogs) and explains how the study design addresses these. The rationale for the trial is logically derived from the cited evidence.
“This study aimed to identify a safe and well-tolerated oral dose of branaplam administered weekly that would lower CSF mHTT levels sufficiently to expect a clinical benefit.”
The VIBRANT-HD trial is described as randomized, double-blind, placebo-controlled with randomization via Interactive Response Technology. Blinding is stated. A sample size calculation was performed. Inclusion/exclusion criteria are described. The primary endpoint was pre-specified. The NHP studies include randomization (though not explicitly stated) and controls. The trial was terminated early, but the design elements are adequately reported.
“All eligible participants were randomized via Interactive Response Technology to one of the treatment arms.”
“VIBRANT-HD was designed as a randomized, double-blind, placebo-controlled study”
“n = 75 for three dose arms (three active treatment groups with n = 20 in each arm and a placebo group with n = 15) was sufficient to reach more than 80% power on average for detecting a dose–response signal using multiple comparison procedures-modeling (MCP-Mod) methodology”
“All eligible participants were randomized via Interactive Response Technology to one of the treatment arms.”
“VIBRANT-HD was designed as a randomized, double-blind, placebo-controlled study”
“n = 75 for three dose arms (three active treatment groups with n = 20 in each arm and a placebo group with n = 15) was sufficient to reach more than 80% power on average for detecting a dose–response signal using multiple comparison procedures-modeling (MCP-Mod) methodology”
For the clinical trial, demographics (age, sex, CAG repeats, disease stage) are reported in Extended Data Table 1. For NHP studies, sex, age, weight, and source are reported. Housing conditions are not described in the text, but this is a minor omission for a toxicology study.
“CAG, cytosine-adenine-guanine; CAP, CAG age product; cUHDRS, composite Unified Huntington’s Disease Rating Scale; SD, standard deviation; TFC, total functional capacity; TMS, total motor score.”
“At dosing initiation, the monkeys were approximately 31–38 months of age and weighed 2.1–3.0 kg.”
“CAG, cytosine-adenine-guanine; CAP, CAG age product; cUHDRS, composite Unified Huntington’s Disease Rating Scale; SD, standard deviation; TFC, total functional capacity; TMS, total motor score.”
“At dosing initiation, the monkeys were approximately 31–38 months of age and weighed 2.1–3.0 kg.”
The clinical trial lists specific ethics committees and states informed consent was obtained. The NHP studies state compliance with the Animal Welfare Act and approval by the local IACUC. Regulatory compliance is stated for both.
“Informed consent was obtained from each participant in writing before screening and before any study-specific procedure was performed.”
“All procedures in the 6-week and 39-week studies were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, the Office of Laboratory Animal Welfare, and fully commensurate with international standards of Good Laboratory Practices and approved by the local Institutional Animal Care and Use Committee.”
“Informed consent was obtained from each participant in writing before screening and before any study-specific procedure was performed.”
“All procedures in the 6-week and 39-week studies were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, the Office of Laboratory Animal Welfare, and fully commensurate with international standards of Good Laboratory Practices and approved by the local Institutional Animal Care and Use Committee.”
Branaplam is named with dose and regimen. The NfL assay kit (Simoa NF-light Advantage Kit, cat. no. 103400, Quanterix) is specified. Software (Monolix, RStudio, SAS) is identified. No antibodies, cell lines, or mycoplasma testing are applicable.
“branaplam 56 mg weekly”
“using a qualified single-molecule array immunoassay according to the manufacturer’s instructions (Simoa NF-light Advantage Kit for SR-X; cat. no. 103400, Quanterix)”
“Branaplam, an orally available HTT messenger RNA splicing modulator, reduces HTT protein levels in vitro and in animal models”
“using a qualified single-molecule array immunoassay according to the manufacturer’s instructions (Simoa NF-light Advantage Kit for SR-X; cat. no. 103400, Quanterix)”
“SAS v.9.4 (SPSS) and higher was used for the analyses.”
The paper states that due to early termination, descriptive statistics were used. No inferential tests are reported for the primary endpoint. For safety findings, percentages are given without p-values. The paper reports mean changes with standard errors, but not confidence intervals. Software is identified. Mathematical plausibility checks are not applicable due to small N and descriptive nature.
“Following the termination of the study, the originally planned analyses of primary, secondary and exploratory endpoints, designed to demonstrate efficacy and identify dose ranges, were no longer applicable. Instead, descriptive summary statistics were provided”
“Mean percentage (s.e.) change from baseline to week 9 in CSF mHTT was −22.3% (3.34; 17 participants) with branaplam 56 mg compared with −6.4% (15.05; 5 participants) with placebo”
“SAS v.9.4 (SPSS) and higher was used for the analyses.”
“Because the early termination of the trial (‘Results’) led to a small sample size, the primary endpoint of mHTT in CSF was summarized descriptively based on the safety analysis set.”
“Mean percentage (s.e.) change from baseline to week 9 in CSF mHTT was −22.3% (3.34; 17 participants) with branaplam 56 mg compared with −6.4% (15.05; 5 participants) with placebo at week 9”
“SAS v.9.4 (SPSS) and higher was used for the analyses.”
The data availability statement provides specific URLs for the protocol and SAP, and describes a managed-access process through CSDR with an independent review panel. This meets the standard for clinical trial data. No code sharing is applicable as no custom code is described.
“Protocol and SAP are available on ClinicaltTrials.gov at https://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/Prot_000.pdf and https://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/SAP_001.pdf , respectively. The reader is able to request the raw data (anonymized) and related documents (for example, clinical study report) of the clinical study by connecting to CSDR ( https://www.clinicalstudydatarequest.com ) and signing a Data Sharing Agreement with Novartis.”
“Protocol and SAP are available on ClinicaltTrials.gov at https://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/Prot_000.pdf and https://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/SAP_001.pdf , respectively. The reader is able to request the raw data (anonymized) and related documents (for example, clinical study report) of the clinical study by connecting to CSDR ( https://www.clinicalstudydatarequest.com ) and signing a Data Sharing Agreement with Novartis.”
Methods are detailed. Trial registration number is provided. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed. A reporting guideline is not explicitly referenced, but the paper includes a CONSORT diagram and follows standard reporting.
“ClinicalTrials.gov identifier: NCT05111249”
“As a limitation, following the early termination of the VIBRANT-HD trial, the number of participants in the placebo arm was one-quarter of that in the branaplam arm, and these participants were followed up for up to 33 weeks, versus 69 weeks for the branaplam arm, which makes the comparison between treatment arms more difficult.”
“The study was funded by Novartis.”
“ClinicalTrials.gov identifier: NCT05111249”
“As a limitation, following the early termination of the VIBRANT-HD trial, the number of participants in the placebo arm was one-quarter of that in the branaplam arm, and these participants were followed up for up to 33 weeks, versus 69 weeks for the branaplam arm, which makes the comparison between treatment arms more difficult.”
“The study was funded by Novartis.”
Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 36 references by DOI: 1 verified — 35 no DOI (shown, not verified).
- NO DOIHuntington’s diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin and its partner Huntingtin-Associated Protein 40: structural and functional considerations in health and diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe biology of huntingtinNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPolyglutamine diseases: emerging concepts in pathogenesis and therapyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntington’s disease: from molecular pathogenesis to clinical treatmentNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin and its role in mechanisms of RNA-mediated toxicityNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITherapeutic approaches to Huntington disease: from the bench to the clinicNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITargeting RNA structures with small moleculesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA miceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAn alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington’s disease patient neuronsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAn orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITherapeutic update on Huntington’s disease: symptomatic treatments and emerging disease-modifying therapiesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin lowering strategies for disease modification in Huntington’s diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risksNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUltrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppressionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITargeting huntingtin expression in patients with Huntington’s diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDiverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINeurofilament light chain: a translational safety biomarker for drug-induced peripheral neurotoxicityNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIOrally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIInsights into the human pharmacokinetics and metabolism of branaplam, a splicing modulator of a survival motor neuron-2 ( SMN2 ) and huntingtin ( HTT ) pre-MRNAs, in infants and adultsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBranaplam translational PK/PD model supported key decision making in Huntington’s diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPredictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational dataNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPrimary cilia and autophagic dysfunction in Huntington’s diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA novel function of huntingtin in the cilium and retinal ciliopathy in Huntington’s disease miceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITominersen in adults with manifest Huntington’s diseaseNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOII010 RNA splicing modulator for Huntington’s disease treatment induces 1 peripheral neuropathyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRNA splicing modulator for Huntington's disease treatment induces peripheral neuropathyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISTP position paper: recommended practices for sampling and processing the nervous system (brain, spinalcord, nerve, and eye) during nonclinical general toxicity studiesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntington disease: clinical care and evaluationNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUnified Huntington’s Disease Rating Scale: reliability and consistencyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMotor, cognitive, and functional declines contribute to a single progressive factor in early HDNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIIdentification of brain disorders by the Stroop Color and Word TestNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISymbol Digit Modalities TestNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairmentNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 of 3 data/code links checked; 2 live; 1 not probed.
- datahttps://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/Prot_000.pdfLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/SAP_001.pdfLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://www.clinicalstudydatarequest.comUNVERIFIEDLiveness indeterminate — content not checked.
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly typo, consistency, clarity.
- MINORtypoAbstract“NCT05111249 (https://clinicaltrials.gov/ct2/show/NCT05111249?term=NCT05111249)”→ Remove duplicate URL or simplify.URL repeated in the same sentence.
- MINORconsistencyResults, Safety findings“85.7% of the participants receiving branaplam 56 mg weekly had one or more signs or symptoms potentially indicative of peripheral neuropathy”→ Ensure consistent use of 'signs or symptoms' vs 'signs and symptoms'.Minor wording inconsistency.
- MINORclarityMethods, Statistical analysis“SAS v.9.4 (SPSS) and higher was used for the analyses.”→ Clarify whether SAS or SPSS was used, or if both were used.Ambiguous software identification.
- MINORtypoAbstract“NCT05111249 (https://clinicaltrials.gov/ct2/show/NCT05111249?term=NCT05111249)”→ Remove redundant query parameter '?term=NCT05111249'.URL is unnecessarily long.
- MINORconsistencyResults, Safety findings“85.7% of the participants receiving branaplam 56 mg weekly had one or more signs or symptoms potentially indicative of peripheral neuropathy”→ Ensure consistent use of 'signs or symptoms' vs 'signs and symptoms' throughout.Minor wording inconsistency.
- MINORclarityMethods, Statistical analysis“SAS v.9.4 (SPSS) and higher was used for the analyses.”→ Clarify whether SAS or SPSS was used, as they are different software.Ambiguous software identification.
The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (missing CIs, no explicit reporting guideline, NHP housing details) as non-fatal. No erratum is warranted, but adding confidence intervals and a reporting guideline statement would strengthen reproducibility.
- 1.MEDIUMreportingAdd an explicit statement of adherence to CONSORT (or other reporting guideline) in the Methods or Reporting Summary.Both reviewers flagged the absence of an explicit reporting guideline statement, which is a standard expectation for clinical trials.
- 2.MEDIUMstatisticsReport confidence intervals for the primary endpoint (CSF mHTT change) alongside the mean and standard error in the Results section.Providing CIs would improve the interpretability of the effect size and is a common reviewer request.
- 3.MEDIUMreportingDescribe housing conditions for the NHP studies (e.g., light cycle, temperature, enrichment) in the Methods section.Both reviewers noted the omission of housing conditions, which is relevant for reproducibility of animal studies.
- 4.LOWcopyeditClarify the software identification in Methods, Statistical analysis: specify whether SAS or SPSS was used, or if both were used.The current phrasing 'SAS v.9.4 (SPSS)' is ambiguous and could confuse readers.
- 5.LOWcopyeditSimplify the ClinicalTrials.gov URL in the Abstract by removing the redundant query parameter '?term=NCT05111249'.The URL is unnecessarily long and could be simplified for clarity.
- 6.LOWcopyeditEnsure consistent use of 'signs or symptoms' vs 'signs and symptoms' throughout the Results section.Minor wording inconsistency was flagged by the copyedit pass.
- 7.LOWdata codeConsider sharing the analysis code used for PK-PD modeling and statistical analyses in a public repository to enhance reproducibility.While not required, sharing code would strengthen reproducibility, as suggested by one reviewer.
- 8.LOWreportingClarify the blinding of the NHP studies or state that blinding was not applicable for toxicology studies.One reviewer suggested clarifying blinding status for the NHP studies to avoid ambiguity.
- 9.LOWreportingInclude a statement on whether any data were excluded from analyses and the reasons, to strengthen outlier handling reporting.One reviewer suggested this to improve transparency about data handling.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.